Table 1.
Clinic-pathological characteristics and treatment outcome of NSCLC with concomitant EGFR mutation and ALK rearrangement
| Patient | Age | Gender | Histology | TNM Stage | Smoker | EGFR mutation | ALK translocation | Response to EGFR TKI | Response to ALK TKI |
|---|---|---|---|---|---|---|---|---|---|
| J.K. Lee et al.4 | 73 | M | ACA | IV | Yes | (Exon19)L747-E749(A750P) | FISH+ | PD | PR, 9 months |
| Miyanaga et al.5 | 55 | F | ACA | IV | No | (Exon19)L747-A750 | FISH+ | PD | SD, 4 months |
| Chen et al.6 | 56 | M | ACA | IV | Yes | (Exon19)E746-A750 | FISH+, RT-PCR+ | SD, 8 months | CR, >22 months |
| Chiari et al.7 | 67 | F | ACA | IV | No | (Exon21)L858R | FISH+ | PR,24 months | PR, 25 months |
| Kuo et al.8 | 72 | F | ACA | IV | No | (Exon19)E746-A750 | RT-PCR+ | PR 7 months | NA |
| Tiseo et al.9 | 48 | M | Adenosq. | IV | No | (Exon19)E746-A750 | FISH+ | PD | NA |
| Tanaka et al.10 | 39 | M | ACA | UK | Yes | (Exon21)L858R | RT-PCR+ | PD | NA |
| Sasaki et al.11 | UK | UK | UK | UK | UK | (Exon21)L858R | FISH+ | PR, 9months | NA |
| Sasaki et al.11 | UK | UK | UK | UK | UK | (Exon19)E746-A750 | FISH+ | PR, 5months | NA |
| our case | 47 | F | ACA | IV | No | (Exon19)E746-A750 | FISH+ | PD | NA |
ACA, adenocarcinoma; Adenosq, adenosquamous carcinoma; ALK, anaplastic lymphoma kinase; CR, complete response; EGFR, epidermal growth factor receptor; F, female; FISH, fluorescence in situ hybridization; M, male; NA, not applicable; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial response; RT-PCR, reverse transcription-polymerase chain reaction; SD, stable disease; TKI, tyrosine kinase inhibitor; TNM, tumor node metastasis; UK, Unknown.